(Total Views: 558)
Posted On: 07/01/2023 8:20:24 AM
Post# of 153916
I was into PRVB, which got bought out by Sanofi recently for their freshly approved diabetes drug Tzield. Tzield delays the onset of T1 diabetes and as a monoclonal antibody my first thought at the time was "I bet our guy Leeron Leemab can work too".
I figure you've got the cascade down pat by now so if I share the MOA below you'll be able to quickly figure out if LL could support or supplant tzield in its efforts.
Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.
I figure you've got the cascade down pat by now so if I share the MOA below you'll be able to quickly figure out if LL could support or supplant tzield in its efforts.
Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.
(5)
(0)
